Clinical Trial Update: Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating intravitreal bevacizumab (Avastin) for pseudophakic macular edema was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystoid Macular Edema
• Pseudophakic Macular Edema

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: Asociación para Evitar la Ceguera en México | Conditions: Cystoid Macular Edema | Phase 3 | Status: WITHDRAWN